Skip to content

Released May 8, 2025, after the close

10-Q filed May 8, 2025, 38 days after period end · 0000950170-25-066991

Q1 2025 · 10-Q
Revenue$9.42M+62.8% vs Q1 2024+28.0% vs Q4 2024
Net Income-$8.82MN/M vs Q1 2024N/M vs Q4 2024
EPS Diluted-$1.17N/M vs Q1 2024no prior Q4 2024 on file
Operating Income-$9,941,000N/M
Operating Cash Flow-$23,439,000N/M
Free Cash Flowderived-$23,439,000N/M
Margins · derived
Operating margin-105.5%+79.9 pt vs Q1 2024
Net margin-93.6%+63.3 pt vs Q1 2024

What the release said

The release

Same quarter

MetricQ1 2025Q1 2024Q1 2023Q1 2022
Revenue$9.42M$5.79M$0.00—
Net Income-$8.82M-$9.08M-$18.95M-$23.09M
EPS Diluted-$1.17-$1.66-$4.46-$0.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR